OOIR: Observatory of International Research

Papers

(The H4-Index of Current Oncology Reports is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?	163
Clinical and Biological Features of Neuroendocrine Prostate Cancer	139
Update on Osteosarcoma	114
Update on Management of Squamous Cell Esophageal Cancer	98
Targeting Apoptosis in Cancer	90
Cardiotoxicity of Immune Checkpoint Inhibitors	65
Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors	61
Determination of Biological Age: Geriatric Assessment vs Biological Biomarkers	61
Immunotherapy for Non-melanoma Skin Cancer	60
Psychological Aspects to Consider in Breast Cancer Diagnosis and Treatment	56
Immunotherapy in Cervical Cancer	52
WEE1 Inhibitor: Clinical Development	52
Bystander effect of antibody–drug conjugates: fact or fiction?	50
Ependymoma: Evaluation and Management Updates	48
CAR-T Therapies in Solid Tumors: Opportunities and Challenges	47
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors	41
Giant Cell Tumor of Bone: An Update	41
Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy	40
VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications	39
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)	39
Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality	37
Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies	37
Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics	33
Disparities in Lung Cancer Treatment	33
The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities	33

The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy	31
ROS1 Targeted Therapies: Current Status	30
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer	30
Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3–5 cm) Unresectable Colorectal Liver Metastases: a System	30
Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation	29
Targeting KRAS in Colorectal Cancer	29